Table 1 Demographics data according to Chronic GVHD history.
Without cGVHD (n = 22) | With chronic GVHD (n = 60) | Odds ratio (95% CI), p-value† | |
|---|---|---|---|
Sex | |||
Male | 14 (63.63%) | 27 (45%) | 0.467 (0.147–1.419), p = 0.2122 |
Female | 8 (36.36%) | 33 (55%) | |
Underlying condition to HSCT | |||
Acute myeloid leukemia | 9 (40.90%) | 8 (13.33%) | 0.222 (0.062–0.804), p = 0.012 |
Chronic myeloid leukemia | 3 (13.63%) | 16 (26.66%) | 2.303 (0.555–13.642), p = 0.25 |
Acute lymphoid leukemia | 5 (22.72%) | 11 (18.33%) | 0.763 (0.206–3.227), p = 0.754 |
Chronic lymphoid leukemia | 0 (0.00%) | 2 (3.33%) | 1.090 (0.098–65.491), p = 1.00 |
Myelodysplastic syndrome | 1 (4.54%) | 5 (8.33%) | 1.909 (0.195–94.519), p = 1.00 |
Nonmalignant disorders | 0 (0.00%) | 1 (1.66%) | 0.993 (0.137–34.217), p = 1.00 |
Donor type | |||
Related | 21 (95.45%) | 57 (95%) | 0.905 (0.016–12.016),p = 1.0 |
Unrelated | 1 (4.54%) | 3 (5%) | |
Conditioning regimen type | |||
Myeloablative | 14 (63.63%) | 41 (68.33%) | 1.233 (0.379–3.808) p = 0.792 |
Reduced intensity | 7 (31.81%) | 6 (10%) | 0.238 (0.058–0.985) p = 0.035 |
Nonmyeloablative | 1 (4.54%) | 13 (21.66%) | 5.809 (0.762–258.367)p = 0.098 |
Source of stem cells | |||
Mobilized blood | 18 (81.81%) | 47 (78.33%) | 0.803 (0.169–3.086) p = 1.0 |
Bone marrow | 4 (18.18%) | 13 (21.66%) | 1.245 (0.324–5.921) p = 1.0000 |
Corneal disease prior to HSCT | 1 (4.54%) | 4 (6.66%) | 1.500 (0.137–77.329) p = 1.0000 |
DED prior to HSCT | 1 (4.54%) | 4 (6.66%) | 1.500 (0.137–77.329) p = 1.0000 |
